Google Spinoff Calico Life Sciences Enters its First Clinical Trial with AbbVie Cancer Drug ABBV-CLS-S579
Calico Life Sciences LLC was founded in 2013 as a Google-backed venture with the goal of combating aging and associated disease. Described […]
Controversy over Heart Attack Study Data and Recommendations Causes Fallout
The definition of what constitutes a heart attack, also known as myocardial infarction (MI), and the data points used to […]
Rheumatoid Arthritis Upadacitinib Gets Positive Opinion from EMA CHMP & Now Awaits Final Authority Marketing Authorization
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for AbbVie’s RINVOQ™( Upadacitinib), […]
Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib
Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in […]
AbbVie Acquires Seattle Area Start-Up to Further Bolster Its Early Stage Oncology Pipeline
Biopharma developing cancer therapies are in demand as the growing industry vies for bigger and more valuable pipelines. Seattle-based, privately […]
AbbVie Will Acquire Allergan in $63 Billion Merger
AbbVie and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan […]
AbbVie Resumes CANOVA Multiple Myeloma Trial After FDA Lifts Partial Hold
AbbVie announced the U.S. FDA has lifted the partial clinical hold placed on CANOVA, a Phase 3 trial evaluating venetoclax […]
VCU Massey Cancer Center Identifies Novel Combo Drug Effective Against AML During Preclinicals
Scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) […]
AbbVie Active at ASCO with Over 40 Abstracts Highlighting its Oncology Pipeline
AbbVie announced in a press release it plans on over 40 abstracts to form its oncology pipeline at this year’s […]
AbbVie’s Treatment for Plaque Psoriasis, Skyrizi, Approved by FDA
AbbVie announced the FDA approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis […]
